DuPont HL (July 2007). “Therapy for and prevention of traveler's diarrhea”. 《Clinical Infectious Diseases》. 45 Suppl 1 (Suppl 1): S78–S84. doi:10.1086/518155. PMID17582576.
Kane JS, Ford AC (2016). “Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome”. 《Expert Review of Gastroenterology & Hepatology》 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID26753693. S2CID13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). “Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation”. 《Expert Opinion on Drug Safety》 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID27149541. S2CID25426888.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, 외. (August 2014). “Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver”. 《Hepatology》 60 (2): 715–735. doi:10.1002/hep.27210. PMID25042402. S2CID3155213.
Triantafyllou K, Sioulas AD, Giamarellos-Bourboulis EJ (2015). “Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome”. 《Mini Reviews in Medicinal Chemistry》 16 (3): 186–192. doi:10.2174/1389557515666150722105340. PMID26202193.
Weinstock LB, Steinhoff M (May 2013). “Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin”. 《Journal of the American Academy of Dermatology》 68 (5): 875–876. doi:10.1016/j.jaad.2012.11.038. PMID23602178.
Pimentel M (January 2016). “Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea”. 《Alimentary Pharmacology & Therapeutics》. 43 Suppl 1 (Suppl 1): 37–49. doi:10.1111/apt.13437. PMID26618924.
DuPont HL (July 2007). “Therapy for and prevention of traveler's diarrhea”. 《Clinical Infectious Diseases》. 45 Suppl 1 (Suppl 1): S78–S84. doi:10.1086/518155. PMID17582576.
Kane JS, Ford AC (2016). “Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome”. 《Expert Review of Gastroenterology & Hepatology》 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID26753693. S2CID13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). “Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation”. 《Expert Opinion on Drug Safety》 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID27149541. S2CID25426888.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, 외. (August 2014). “Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver”. 《Hepatology》 60 (2): 715–735. doi:10.1002/hep.27210. PMID25042402. S2CID3155213.
Triantafyllou K, Sioulas AD, Giamarellos-Bourboulis EJ (2015). “Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome”. 《Mini Reviews in Medicinal Chemistry》 16 (3): 186–192. doi:10.2174/1389557515666150722105340. PMID26202193.
Weinstock LB, Steinhoff M (May 2013). “Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin”. 《Journal of the American Academy of Dermatology》 68 (5): 875–876. doi:10.1016/j.jaad.2012.11.038. PMID23602178.
Pimentel M (January 2016). “Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea”. 《Alimentary Pharmacology & Therapeutics》. 43 Suppl 1 (Suppl 1): 37–49. doi:10.1111/apt.13437. PMID26618924.
Kane JS, Ford AC (2016). “Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome”. 《Expert Review of Gastroenterology & Hepatology》 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID26753693. S2CID13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). “Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation”. 《Expert Opinion on Drug Safety》 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID27149541. S2CID25426888.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, 외. (August 2014). “Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver”. 《Hepatology》 60 (2): 715–735. doi:10.1002/hep.27210. PMID25042402. S2CID3155213.